BridgeBio Oncology Therapeutics, Inc.

8-K Director or officer change; Shareholder vote results Jun 22, 2026 10-Q Quarter ended 2026-03-31 May 12, 2026 8-K Results of operations (earnings release) May 12, 2026 8-K Director or officer change Apr 29, 2026 8-K Director or officer change; Regulation FD disclosure Apr 23, 2026 8-K Director or officer change Mar 26, 2026 10-K Fiscal year ended 2025-12-31 Mar 5, 2026 8-K Results of operations (earnings release) Mar 5, 2026 8-K Other events Jan 7, 2026 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release) Nov 12, 2025 8-K Entered a material agreement; Completed an acquisition or disposition; Unregistered sale of equity; Modified rights of security holders; Changed accountants; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Item 5.06; Regulation FD disclosure; Other events Aug 13, 2025 8-K Regulation FD disclosure Aug 6, 2025 8-K Shareholder vote results Aug 4, 2025 10-Q Quarter ended 2025-06-30 Aug 1, 2025 8-K Regulation FD disclosure Jul 11, 2025 10-Q Quarter ended 2025-03-31 May 15, 2025 10-K Fiscal year ended 2024-12-31 Mar 11, 2025 8-K Entered a material agreement; Unregistered sale of equity Mar 3, 2025 8-K Regulation FD disclosure Feb 28, 2025 8-K Director or officer change Feb 10, 2025 10-Q Quarter ended 2024-09-30 Nov 14, 2024 10-Q Quarter ended 2024-06-30 Aug 14, 2024 10-Q Quarter ended 2024-03-31 May 15, 2024 8-K Other events Feb 20, 2024 8-K Entered a material agreement; Unregistered sale of equity; Director or officer change; Amended charter or bylaws; Other events Feb 14, 2024 4 Jul 6, 2026 4 Jul 6, 2026 4 Jul 6, 2026 4 Jul 6, 2026 SCHEDULE 13D/A Jul 6, 2026 4 Jul 6, 2026 424B3 Jun 22, 2026 4 Jun 18, 2026 4 Jun 18, 2026 4 Jun 18, 2026 4 Jun 18, 2026 4 Jun 18, 2026 4 Jun 18, 2026 4 Jun 18, 2026